Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Lipigon Pharmaceuticals

Less than 1K followers
Overview
Ownership
Investor views
All
Press releases
ShowingAll content types

Regulatory press release03.12.2025 klo 19.55

Lipigon Pharmaceuticals presents top-line data from the Phase II clinical trial of Lipisense in patients with elevated blood lipid levels

Lipigon Pharmaceuticals
Press release21.11.2025 klo 13.19

Redeye: Lipigon (Q3 Review) - Topline Before Year-End

Lipigon Pharmaceuticals
Press release14.10.2025 klo 23.58

Lipigon Pharmaceuticals reports last patient visit in the three-month follow-up of its Phase II clinical study with Lipisense

Lipigon Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release26.08.2025 klo 15.28

Redeye: Lipigon Q2 2025 - Last Patient In

Lipigon Pharmaceuticals
Regulatory press release06.07.2025 klo 10.03

Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense®

Lipigon Pharmaceuticals
Press release27.05.2025 klo 09.36

Redeye: Lipigon Q1 2025 - 64.5% Subscription Rate in the Rights Issue

Lipigon Pharmaceuticals
Press release31.03.2025 klo 09.25

Redeye: Lipigon Q4 2024 - Rights issue funds 2025

Lipigon Pharmaceuticals
Regulatory press release20.03.2025 klo 13.15

Lipigon Pharmaceuticals' commercial partner announces positive results from Phase I clinical trial with Lipisense

Lipigon Pharmaceuticals
Press release21.11.2024 klo 15.12

Redeye: Lipigon Q3 2024 - First Patient Recruited

Lipigon Pharmaceuticals
Regulatory press release21.11.2024 klo 11.00

Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®

Lipigon Pharmaceuticals
Press release18.09.2024 klo 13.51

Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®

Lipigon Pharmaceuticals
Press release28.08.2024 klo 08.43

Redeye: Lipigon Q2 2024 - Marea Launched

Lipigon Pharmaceuticals
Regulatory press release09.07.2024 klo 15.00

Lipigon Receives Milestone Payment of USD 1 Million from Leaderna for Approval of Phase I Bridging Study

Lipigon Pharmaceuticals
Press release20.06.2024 klo 09.30

New Publication: The ANGPTL4 Protein May Reduce the Risk of Cardiovascular Disease and Diabetes

Lipigon Pharmaceuticals
Press release29.05.2024 klo 09.03

Redeye: Lipigon Q1 2024 - Phase II Underway

Lipigon Pharmaceuticals
Press release15.05.2024 klo 09.28

Lipigon and Leaderna Collaboration on Lipisense® Shows Good Progress

Lipigon Pharmaceuticals
Regulatory press release14.05.2024 klo 08.53

Lipigon collaborates with University of Washington on lung damage project

Lipigon Pharmaceuticals
Press release23.02.2024 klo 09.08

Redeye: Lipigon Q4 2023 - Phase II study approved

Lipigon Pharmaceuticals
Press release07.02.2024 klo 17.00

The Swedish Medical Products Agency approves Lipigon's phase II study with Lipisense®

Lipigon Pharmaceuticals
Press release12.12.2023 klo 11.11

Lipisense® progressing to Phase II - what comes next?

Lipigon Pharmaceuticals